uniQure stock
QURENASDAQuniQure N.V., HealthcareISIN NL0010696654
35Score 35 out of 100, Weak
Price and trend
55 / 100
Price history
−18% in one yearThe chart shows daily closes over 13 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 17% below it.
Since July 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 58).
The price is 52% below its 52-week high. Largest decline in 13 years: 95% (June 2019 to July 2024).
Chart figures for advanced users
- SMA 50$29.92
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$29.64
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)58
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$9.03
- The lowest closing price of the last twelve months.
- Resistance$51.05
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- uniQure N.V. belongs to the Biotechnology industry (Netherlands) and, with a market value of $1.73B, is number 137 of 289 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $16.1M (down 40.6% year on year) and a loss of $198.97M.
- For fiscal 2026, analysts expect on average revenue of $21.21M (up 31.8%) and adjusted earnings per share of −$3.79.
Show more
- MEQIRI Score 35 out of 100 (Weak): rank 615 of 702 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $668.46M, financial debt $62.37M.Stability 52
Weaknesses
- DilutionShare count up 29% since 2020.Capital allocation 18
- Volatile share priceVolatility 132% a year over the last 12 months.Stability 52
- Loss-makingLoss of $232.9M over the last 12 months.Fundamentals 17
The score is held back by fundamentals and profitability.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 36 to 35.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredNo fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 28% on the twelve months before. Revenue has changed sharply in recent years: $16.1M in 2025 after $27.12M in 2024. From 2023 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 90%, operating −1167%, net −1236%. Last 12 months: net −100%. From 2023 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Debt & balance sheet
latest quarterDebt is low, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 1 Mar 2027in 108 days
- Last reported
- 4 Nov 2026EPS reported −$0.88 (expected −$0.92)above expectations
Analyst estimates
Analysts have raised their 2027 earnings estimate by 5.2% since 15 Oct 2026.
- Earnings per share
- −$3.79+2.6%
- Revenue
- $21.21M−9.6%
- Earnings per share
- −$2.92+5.2%
- Revenue
- $116.91M−3.2%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 11 insiders sold, $17.01M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Meek David D.Sale
6 Nov 2026, Board
- Shares
- 9,080
- Price
- $21.25
- Value
- $192,950
- Kapusta Matthew CSale
2 Jul 2026, CEO, Managing Director
- Shares
- 21,082
- Price
- $45.16
- Value
- $952,051
- Abi-Saab WalidSale
30 Jun 2026, Chief Medical Officer
- Shares
- 30,000
- Price
- $46.42
- Value
- $1.39M
Show 20 more
- Kaye JackSale
30 Jun 2026, Board
- Shares
- 21,167
- Price
- $46.44
- Value
- $983,030
- Abi-Saab WalidSale
26 Jun 2026, Chief Medical Officer
- Shares
- 1,434
- Price
- $46.86
- Value
- $67,197
- Kapusta Matthew CSale
25 Jun 2026, CEO, Managing Director
- Shares
- 28,716
- Price
- $50.02
- Value
- $1.44M
- Kapusta Matthew CSale
24 Jun 2026, CEO, Managing Director
- Shares
- 6,696
- Price
- $50.00
- Value
- $334,800
- Kapusta Matthew CSale
18 Jun 2026, CEO, Managing Director
- Shares
- 41,671
- Price
- $50.00
- Value
- $2.08M
- Kapusta Matthew CSale
17 Jun 2026, CEO, Managing Director
- Shares
- 164,429
- Price
- $44.32
- Value
- $7.29M
- Balachandran MadhavanSale
17 Jun 2026, Board
- Shares
- 11,685
- Price
- $45.06
- Value
- $526,485
- Kaye JackSale
17 Jun 2026, Board
- Shares
- 5,295
- Price
- $42.57
- Value
- $225,408
- Balachandran MadhavanSale
15 Jun 2026, Board
- Shares
- 10,000
- Price
- $27.85
- Value
- $278,500
- Potts JeannetteSale
15 Jun 2026, Chief Legal Officer
- Shares
- 5,237
- Price
- $27.67
- Value
- $144,908
- Meek David D.Sale
11 Jun 2026, Board
- Shares
- 1,993
- Price
- $27.06
- Value
- $53,931
- Gut RobertSale
11 Jun 2026, Board
- Shares
- 2,726
- Price
- $27.06
- Value
- $73,766
- O'Keefe KylieSale
11 Jun 2026, Chief Customer & Strat Officer
- Shares
- 15,936
- Price
- $27.06
- Value
- $431,228
- Springhorn Jeremy P.Sale
11 Jun 2026, Board
- Shares
- 1,993
- Price
- $27.06
- Value
- $53,931
- Post Leonard ESale
11 Jun 2026, Board
- Shares
- 1,993
- Price
- $27.06
- Value
- $53,931
- Kaye JackSale
11 Jun 2026, Board
- Shares
- 1,993
- Price
- $27.06
- Value
- $53,931
- Jacques Rachelle SuzanneSale
11 Jun 2026, Board
- Shares
- 1,993
- Price
- $27.06
- Value
- $53,931
- Balachandran MadhavanSale
11 Jun 2026, Board
- Shares
- 1,993
- Price
- $27.06
- Value
- $53,931
- Gut RobertSale
10 Jun 2026, Board
- Shares
- 7,552
- Price
- $26.05
- Value
- $196,720
- Kaye JackSale
3 Jun 2026, Board
- Shares
- 2,645
- Price
- $30.01
- Value
- $79,376
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at uniQure
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 35
- Sector median
- 53
Categories against the sector medianMedian of 702 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Fortrea HoldingsFTRE $1.9B41
- Zenas BioPharmaZBIO $1.87B37
- ZymeworksZYME $1.84B59
- Hemab Therapeutics HoldingsCOAG $1.84B45
- Sarepta TherapeuticsSRPT $1.72B39
- Kailera TherapeuticsKLRA $1.72B41
- Stoke TherapeuticsSTOK $1.71B37
- Taysha Gene TherapiesTSHA $1.71B35
ETFs that hold uniQure
Held by 5 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Ageing Population UCITS ETF2B77 | 0.11% | 0.40% | €813.42M |
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.10% | 0.35% | €1.25B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.01% | 0.43% | €2.5B |
Show 2 more
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.01% | 0.10% | €395.74M |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.01% | 0.35% | €8.27B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Aug 2022)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.